GYRE
Price
$8.08
Change
+$0.05 (+0.62%)
Updated
Jun 17, 04:59 PM (EDT)
Capitalization
730.72M
63 days until earnings call
MIST
Price
$1.73
Change
+$0.01 (+0.58%)
Updated
Jun 17 closing price
Capitalization
92.49M
49 days until earnings call
Interact to see
Advertisement

GYRE vs MIST

Header iconGYRE vs MIST Comparison
Open Charts GYRE vs MISTBanner chart's image
Gyre Therapeutics
Price$8.08
Change+$0.05 (+0.62%)
Volume$1.65K
Capitalization730.72M
Milestone Pharmaceuticals
Price$1.73
Change+$0.01 (+0.58%)
Volume$577.48K
Capitalization92.49M
GYRE vs MIST Comparison Chart in %
Loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GYRE vs. MIST commentary
Jun 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a Hold and MIST is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 18, 2025
Stock price -- (GYRE: $8.09 vs. MIST: $1.73)
Brand notoriety: GYRE and MIST are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 37% vs. MIST: 51%
Market capitalization -- GYRE: $730.72M vs. MIST: $92.49M
GYRE [@Biotechnology] is valued at $730.72M. MIST’s [@Biotechnology] market capitalization is $92.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $342.74B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 1 FA rating(s) are green whileMIST’s FA Score has 0 green FA rating(s).

  • GYRE’s FA Score: 1 green, 4 red.
  • MIST’s FA Score: 0 green, 5 red.
According to our system of comparison, both GYRE and MIST are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 4 TA indicator(s) are bullish while MIST’s TA Score has 5 bullish TA indicator(s).

  • GYRE’s TA Score: 4 bullish, 6 bearish.
  • MIST’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MIST is a better buy in the short-term than GYRE.

Price Growth

GYRE (@Biotechnology) experienced а -10.11% price change this week, while MIST (@Biotechnology) price change was -1.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.14%. For the same industry, the average monthly price growth was +8.92%, and the average quarterly price growth was +2.18%.

Reported Earning Dates

GYRE is expected to report earnings on Aug 19, 2025.

MIST is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($731M) has a higher market cap than MIST($92.5M). MIST YTD gains are higher at: -26.695 vs. GYRE (-33.636). GYRE has higher annual earnings (EBITDA): 12.1M vs. MIST (-48.18M). MIST has more cash in the bank: 56M vs. GYRE (29.9M). GYRE has less debt than MIST: GYRE (1.59M) vs MIST (55.6M). GYRE has higher revenues than MIST: GYRE (101M) vs MIST (0).
GYREMISTGYRE / MIST
Capitalization731M92.5M790%
EBITDA12.1M-48.18M-25%
Gain YTD-33.636-26.695126%
P/E Ratio404.50N/A-
Revenue101M0-
Total Cash29.9M56M53%
Total Debt1.59M55.6M3%
FUNDAMENTALS RATINGS
GYRE vs MIST: Fundamental Ratings
GYRE
MIST
OUTLOOK RATING
1..100
6679
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
91100
SMR RATING
1..100
63100
PRICE GROWTH RATING
1..100
9043
P/E GROWTH RATING
1..100
7100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MIST's Valuation (56) in the Pharmaceuticals Major industry is somewhat better than the same rating for GYRE (94) in the null industry. This means that MIST’s stock grew somewhat faster than GYRE’s over the last 12 months.

GYRE's Profit vs Risk Rating (91) in the null industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that GYRE’s stock grew similarly to MIST’s over the last 12 months.

GYRE's SMR Rating (63) in the null industry is somewhat better than the same rating for MIST (100) in the Pharmaceuticals Major industry. This means that GYRE’s stock grew somewhat faster than MIST’s over the last 12 months.

MIST's Price Growth Rating (43) in the Pharmaceuticals Major industry is somewhat better than the same rating for GYRE (90) in the null industry. This means that MIST’s stock grew somewhat faster than GYRE’s over the last 12 months.

GYRE's P/E Growth Rating (7) in the null industry is significantly better than the same rating for MIST (100) in the Pharmaceuticals Major industry. This means that GYRE’s stock grew significantly faster than MIST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GYREMIST
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 8 days ago
81%
Bullish Trend 1 day ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 5 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 1 day ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KUYAF0.280.02
+7.17%
Kuya Silver Corp.
TSCDY16.31-0.03
-0.18%
Tesco PLC
CSLLY78.18-0.29
-0.37%
CSL Ltd.
HCHDF3.35-0.02
-0.59%
Hochschild Mining PLC
ALSMY2.10-0.04
-1.87%
Alstom

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with SPRC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then SPRC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
+0.50%
SPRC - GYRE
38%
Loosely correlated
-2.62%
AURA - GYRE
38%
Loosely correlated
-0.31%
PYXS - GYRE
38%
Loosely correlated
+0.83%
BEAM - GYRE
38%
Loosely correlated
-2.58%
CRBU - GYRE
37%
Loosely correlated
+0.90%
More